55934-10-6

Basic information

• Product Name: 1H-Indene-4-carboxylic acid, 2,3-dihydro-1-oxo-, Methyl ester
• Synonyms: 1H-Indene-4-carboxylic acid, 2,3-dihydro-1-oxo-, Methyl ester;4-Indancarboxylic acid, 1-oxo-, Methyl ester;Methyl 1-oxoindan-4-carboxylate;Methyl 1-oxo-2,3-dihydro-1H-indene-4-carboxylate;1-Oxo-indan-4-carboxylic acid methyl ester;methyl 1-oxo-2,3-dihydroindene-4-carboxylate
• CAS NO: 55934-10-6
• Molecular Formula: C₁₁H₁₀O₃
• Molecular Weight: 190.1953
• EINECS: -0
• Mol File: 55934-10-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 102-103 °C
• Boiling Point: 346.1±31.0 °C(Predicted)
• Appearance: /
• Density: 1.243±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 1H-Indene-4-carboxylic acid, 2,3-dihydro-1-oxo-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indene-4-carboxylic acid, 2,3-dihydro-1-oxo-, Methyl ester(55934-10-6)
• EPA Substance Registry System: 1H-Indene-4-carboxylic acid, 2,3-dihydro-1-oxo-, Methyl ester(55934-10-6)

Safety Data

• Hazardous Substances Data: 55934-10-6(Hazardous Substances Data)

Usage

General Description

1H-Indene-4-carboxylic acid, 2,3-dihydro-1-oxo-, methyl ester is a chemical compound with the molecular formula C12H10O3. It is a methyl ester derivative of 1H-indene-4-carboxylic acid, and it is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceuticals. It is a colorless to pale yellow liquid with a characteristic odor, and it is insoluble in water but soluble in organic solvents such as ethanol and diethyl ether. 1H-Indene-4-carboxylic acid, 2,3-dihydro-1-oxo-, methyl ester is also known for its potential biological activity, and it has been studied for its anti-inflammatory and antiviral properties. Overall, 1H-Indene-4-carboxylic acid, 2,3-dihydro-1-oxo-, methyl ester is an important chemical in pharmaceutical synthesis and research.

Upstream product

• 186581-53-3 diazomethane 
• 56461-20-2 1-oxoindane-4-carboxylic acid 
• 86031-42-7 4-Indancarbonsaeuremethylester 
• 4044-54-6 2,3-dihydro-1H-indene-4-carboxylic acid 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 
• 119-67-5 o-carboxybenzaldehyde 
• 1370650-73-9 methyl 2-(3-chloro-3-oxopropyl)benzoate 
• 4122-56-9 methyl o-formylbenzoate 
• 81329-74-0 3-(2-(methoxycarbonyl)phenyl)propanoic acid 
• 612-40-8 2-carboxycinnamic acid 
• 776-79-4 2-(2-carboxyethyl)benzoic acid 

Relevant articles and documents

Lewis acid-mediated generation of bicyclo[5.3.0]decanes and bicyclo[4.3.0]nonanes

(Chemical Equation Presented) Fragmentation of the cyclobutane-containing adducts generated from intramolecular cycloadditions of cyclobutadiene with olefins provides rapid entry into bicyclo[5.3.0]decane and bicyclo[4.3.0]nonane ring systems. Whereas ear

Synthesis, biological evaluation and molecular docking studies of indeno [1, 2-c] pyrazol derivatives as inhibitors of mitochondrial malate dehydrogenase 2 (MDH2)

Hypoxia inducible factor-1 (HIF-1) is a pivotal transcription factor, which is strongly correlated with the induction of angiogenesis, tumor survival, metastasis, and cell proliferation, making it a pivotal therapeutic target for solid tumor therapeutic agents. Herein, a new series of multi-functional chemical probes were designed including principal groups, viz. adamantyl and indene, at various locations of the parent compound LW6. Molecular docking studies were performed on the designed compounds and their relationship with HIF-1α and malate dehydrogenase 2 (MDH2). Inhibition of MDH2 by our compounds was expected to decrease the NADH level. Indeed, treatment of the breast cancer cell line 4T1 led to a strong reduction of the NADH concentration. The greatest reduction in NADH production in mitochondria was observed with (E)-3-(4-((3r, 5r, 7r)-adamantan-1-yl) phenoxy)-N-(5-(piperidine-1-carbonyl)-1, 4-dihydroindeno [1, 2-c] pyrazol-3-yl) acrylamide (18: IC50 = 59 nM), and has the best inhibitory potential under hypoxic conditions (MCF-7: IC50 = 57 nM). This compound also gave one of the highest docking “higher than the score obtained with LW6 in parallel (?31.63 kcal/mol) in the initial docking runs (PDB Code: 4WLO). Other related compounds with good yields were also synthesized from docking results, and all the synthesized compounds (14, 18, 22, 26, 29, 30) were evaluated in vitro on human adenocarcinoma cell lines.

METHODS USING HDAC11 INHIBITORS

The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain amino-pyridine-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.